- Oil prices tumble on easing Middle East fears
- Oil prices hit by easing Middle East fears, most Asian markets rise
- Hopes pinned on peace across Taiwan Strait after drills
- Belgian pathologist and literary star gives 'voice to the dead'
- East Timor fights new battles 25 years after independence vote
- Oil prices drop on easing fears over Middle East, most markets rise
- Reoxygenating oceans: startups lead the way in Baltic Sea
- King Charles III heads to Australia and Commonwealth meeting
- Wall Street stocks hit fresh records as oil prices slide
- Strike-hit Boeing leaves experts puzzled by strategy
- NASA launches probe to study if life possible on icy Jupiter moon
- EVs seek to regain sales momentum at Paris Motor Show
- NASA probe Europa Clipper lifts off for Jupiter's icy moon
- 'Unsustainable' housing crisis bedevils Spain's socialist govt
- Stocks shrug off China disappointment but oil slides
- Stocks diverge, oil retreats as China disappoints markets
- Trio wins economics Nobel for work on wealth inequality
- Ex-Stasi officer jailed over 1974 Berlin border killing
- Shanghai stocks gain after stimulus briefing as markets rally
- Shanghai stocks gain after stimulus briefing as Asian markets rally
- Nearly 90, but opera legend Kabaivanska is still calling tune
- With inflation down, ECB eyes faster tempo of rate cuts
- Is life possible on a Jupiter moon? NASA goes to investigate
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- In milestone, SpaceX 'catches' megarocket booster after test flight
- In a first, SpaceX 'catches' megarocket booster after test flight
- Bangladeshi Hindus shrug off attack worries to celebrate festival
- Ubisoft fears assassin's hit over falling sales
- Vietnam, China hold talks on calming South China Sea tensions
- SpaceX will try to 'catch' giant Starship rocket shortly before landing
- Japan's former empress Michiko discharged after surgery: reports
- Japan's former empress Michiko discharged after surgey: reports
- 'Little Gregory' murder haunts France 40 years on
- Tariffs, tax cuts, energy: What is in Trump's economic plan?
- Amazon wants to be everything to everyone
- Jewish school in Canada hit by gunfire for second time
- With medical report Harris seeks to play health card against Trump
- China-EU EV tariff talks in Brussels end with 'major differences': Beijing
- Buried Nazi past haunts Athens on liberation anniversary
- Harris to release medical report confirming fitness for presidency: campaign
- Nobel prize a timely reminder, Hiroshima locals say
- China offers $325 bn in fiscal stimulus for ailing economy
- Small Quebec company dominates one part of NHL hockey: jerseys
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Want to film in Paris? No sexism allowed
- US, European markets rise as investors weigh rates, earnings
- In Colombia, children trade plastic waste for school supplies
- JPMorgan Chase profits top estimates, bank sees 'resilient' US economy
- Little progress at key meet ahead of COP29 climate summit
First no-prescription birth control pill approved in US
US health authorities on Thursday approved the first over-the-counter birth control pill in the country, dramatically widening access to contraception for women in the United States where abortion rights are increasingly under assault.
The medication, Opill, will become available in pharmacies and supermarkets as well as online early next year, the manufacturer Perrigo said in a statement.
More than 100 countries already allow contraceptive pills to be sold over the counter. But in the United States approval comes after the Supreme Court last year scrapped federal abortion protections and the procedure is now banned in several states.
"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the Food and Drug Administration's Center for Drug Evaluation and Research in a statement.
"When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
The agency warned, however, that the pill should not be taken by women who have or have ever had breast cancer.
- 'Victory for equity' -
Almost half of the 6.1 million pregnancies in the United States each year are unintended, according to the FDA.
Allowing women to access the progestin-only daily contraceptive pill without needing to see a doctor first "may help reduce the number of unintended pregnancies and their potential negative impacts," the FDA statement said.
The pill, produced by the pharmaceutical company HRA Pharma, which was recently acquired by Perrigo, had already been authorized for prescription in the United States for a number of years.
"This moment is a victory for equity, human rights, public health, and evidence-based research—and especially in light of the ongoing attacks on reproductive health and rights, it is a reason to celebrate," said the Free the Pill coalition, a leading advocacy group.
Experts say the decision could be especially significant for teenage girls who may find it harder to get to the doctor, particularly if they want to do it on their own.
"An over-the-counter birth control pill has the potential to transform the way people access contraception, especially those who face the most barriers in our health care system, including LGBTQIA+ folks, people of color, and those working to make ends meet," said Lin-Fan Wang, a family physician serving the LGBTQ community and a Free the Pill member.
In May, an expert advisory committee convened by the FDA unanimously voted in favor of authorizing the sale of Perrigo without a prescription, judging that the benefits outweighed the risks.
The contraceptive pill, taken daily at the same time, prevents a pregnancy during sexual intercourse.
A.Leibowitz--CPN